secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001628280-23-005822
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY
-----------------------------------------------------------

- Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.
- Net loss narrowed to $443.3M from $704.5M in 2021; cash position $1.0B as of Dec 31, 2022.
- Expects commercial profitability in 2023 and overall corporate profitability by end of 2025.
- Key pipeline milestones: BLA submission for efgartigimod in gMG, NDA for repotrectinib, and initiation of KarXT bridging study in China.
- Appointed Michel Vounatsos to Board and Rafael Amado as President, Global Oncology R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/0001628280-23-005822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/zlab-20230301.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer